QTRX vs. SIBN, TRNS, EYPT, ALNT, LAB, CTKB, AEHR, QSI, SENS, and MASS
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include SiBone (SIBN), Transcat (TRNS), EYEPOINT PHARMACEUTICALS (EYPT), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Senseonics (SENS), and 908 Devices (MASS).
Quanterix vs. Its Competitors
SiBone (NASDAQ:SIBN) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.
In the previous week, SiBone's average media sentiment score of 1.89 beat Quanterix's score of 0.00 indicating that SiBone is being referred to more favorably in the media.
SiBone has a net margin of -15.03% compared to Quanterix's net margin of -36.82%. Quanterix's return on equity of -15.07% beat SiBone's return on equity.
SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.
SiBone presently has a consensus price target of $22.50, suggesting a potential upside of 21.89%. Quanterix has a consensus price target of $15.60, suggesting a potential upside of 126.91%. Given Quanterix's higher probable upside, analysts plainly believe Quanterix is more favorable than SiBone.
98.1% of SiBone shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 6.9% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
SiBone has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Summary
SiBone beats Quanterix on 10 of the 15 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
This page (NASDAQ:QTRX) was last updated on 7/6/2025 by MarketBeat.com Staff
